Please assess the completion status of the following clinical trial:

Trial Title: Study of Temzolomide and Gleevec in Advanced Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed melanoma that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective~* Prior chemotherapy, immunotherapy, radiation therapy (Phase I portion only), cytokine, biologic, or vaccine therapy is permitted, however no prior treatment with temozolomide~* Measurable disease~* Performance status \<= 2~* Life expectancy greater than 3 months~Exclusion Criteria:~* No prior treatment with temozolomide or imatinib mesylate~* Organ allografts~* Prior radiotherapy, or prior intratumor injection therapy, to areas of measurable disease that are used as target indicator lesions, unless progression has occurred at that site or measurable disease has developed outside the treatment area~* Pregnancy or lactation~* History of second cancer~* Known hypersensitivity to temozolomide or imatinib~* Use of any experimental therapy within 3 weeks prior to baseline evaluations done prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: (Type: EXPERIMENTAL): Temozolomide plus imatinib

Based on this trial design, predict the completion outcome and termination type (if applicable).